NCT04564781招募中不适用
A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-muscle Invasive Bladder Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 10
- 主要终点
- Sensitivity and specificity of multiplex immunoassay will be confirmed by surveillance cystoscopy.
研究概览
简要总结
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Patients must have histologically proven Ta, carcinoma in situ (CIS) or T1 stage urothelial cell carcinoma of the bladder diagnosed within 90 days prior to scheduled BCG
- •Patients must have had all grossly visible papillary tumors removed within 30 days prior to scheduled BCG or cystoscopy confirming no grossly visible papillary tumors within 30 days prior to scheduled BCG
- •Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis demonstrating no evidence of nodal involvement or metastatic disease (CT scan or MRI scan) within 90 days prior to scheduled BCG
- •Patients must have intermediate or high-grade bladder cancer as defined by 2004 WHO/ISUP classification
- •Patients must not have pure squamous cell carcinoma or adenocarcinoma.
- •Patients' disease must not have micropapillary components.
- •Patients must have no evidence of upper tract (renal pelvis or ureters) cancer confirmed by one of the following tests performed within 90 days prior to BCG: CT urogram, intravenous pyelogram, MR urogram, or retrograde pyelograms.
- •No other prior non-bladder malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
- •Participants may be treated with immediate post-operative intravesical instillation of a chemotherapeutic agent
- •Scheduled to undergo intravesical BCG therapy within 4 weeks of signing consent.
- •Willing and able to give written informed consent (see Appendix 1)
- •Willing to provide voided urine sample
排除标准
- •Previous intravesical BCG therapy
- •Patients must not be taking oral glucocorticoids at the time of registration.
- •Patients must not be planning to receive concomitant biologic therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study.
- •Patients must not have known history of tuberculosis.
- •Have incomplete TUR, i.e., visible residual disease
- •Have had radical cystectomy
- •Have a known active urinary tract infection or urinary retention
- •Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwise repeat.
- •Have ureteral stents, nephrostomy tubes or bowel interposition
- •Have recent genitourinary instrumentation (within 7 days prior to signing consent)
- •Be unable or unwilling to complete BCG induction and maintenance regimen
结局指标
主要结局
Sensitivity and specificity of multiplex immunoassay will be confirmed by surveillance cystoscopy.
时间窗: present through 04/30/2027
次要结局
- Sensitivity and specificity of multiplex immunoassay will be compared to panel of urinary cytokines.(present through 04/30/2027)
研究者
Charles Rosser
Professor
Cedars-Sinai Medical Center
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological MarkersBladder CancerNCT04723121Mansoura University204
进行中（未招募）
3 期
Intravesical BCG vs GEMDOCE in NMIBCNon-muscle-invasive Bladder CancerNCT05538663ECOG-ACRIN Cancer Research Group870
进行中（未招募）
不适用
A Diagnostic for the Early Detection of Bladder CancerBladder CancerNCT05347342Cedars-Sinai Medical Center173
招募中
不适用
Validation of novel biomarkers for treatment response to rush oral immunotherapy for food allergy in childreFood allergyJPRN-UMIN000029742Department of Clinical Research, Mie National Hospital30
尚未招募
Unknown
Biomarker Screening for Immunotherapy Response Evaluation using Microneedle Patch in Patients with Allergic RhinitisDiseases of the respiratory systemKCT0008534Yonsei University Health System, Severance Hospital30